[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Renne, S.L., Sarcognato, S., Sacchi, D., et al. (2021) Hepatocellular Car-cinoma: A Clinical and Pathological Overview. Pathologica, 113, 203-217. https://doi.org/10.32074/1591-951X-295
|
[3]
|
Zhang, W., He, H., Zang, M., et al. (2017) Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. Gastroenterology, 153, 249-262. https://doi.org/10.1053/j.gastro.2017.03.024
|
[4]
|
Altekruse, S.F., Henley, S.J., Cucinelli, J.E. and McGlynn, K.A. (2014) Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States. American Journal of Gastroenterology, 109, 542-553.
https://doi.org/10.1038/ajg.2014.11
|
[5]
|
Xu, L., Kim, Y., Spolverato, G., Gani, F. and Pawlik, T.M. (2016) Racial Disparities in Treatment and Survival of Patients with Hepatocellular Carcinoma in the United States. Hepatobiliary Sur-gery and Nutrition, 5, 43-52.
https://doi.org/10.21037/hbsn.2016.12.03
|
[6]
|
Zhang, G., Li, R., Deng, Y. and Zhao, L. (2018) Conditional Sur-vival of Patients with Hepatocellular Carcinoma: Results from the Surveillance, Epidemiology, and End Results Registry. Expert Review of Gastroenterology & Hepatology, 12, 515-523. https://doi.org/10.1080/17474124.2018.1453806
|
[7]
|
Cheng, A.-L., Kang, Y.-K., Chen, Z., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
|
[8]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib ver-sus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[9]
|
Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Dou-ble-Blind, Placebo-Controlled, Phase 3 Trial. Lancet, 389, 56-66.
https://doi.org/10.1016/S0140-6736(16)32453-9
|
[10]
|
Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 379, 54-63. https://doi.org/10.1056/NEJMoa1717002
|
[11]
|
Zhu, A.X., Kang, Y.K., Yen, C.J., et al. (2019) Ramu-cirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 282-296. https://doi.org/10.1016/S1470-2045(18)30937-9
|
[12]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[13]
|
Hinshaw, D.C. and Shevde, L.A. (2019) The Tumor Microenvi-ronment Innately Modulates Cancer Progression. Cancer Research, 79, 4557-4566. https://doi.org/10.1158/0008-5472.CAN-18-3962
|
[14]
|
Kudo, M. (2019) Immuno-Oncology Therapy for Hepato-cellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 8, 221-238. https://doi.org/10.1159/000501501
|
[15]
|
Gao, B., Jeong, W.-I. and Tian, Z. (2008) Liver: An Organ with Predomi-nant Innate Immunity. Hepatology, 47, 729-736. https://doi.org/10.1002/hep.22034
|
[16]
|
Gao, Q., Wang, X.-Y., Qiu, S.J., et al. (2009) Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clinical Cancer Research, 15, 971-979.
https://doi.org/10.1158/1078-0432.CCR-08-1608
|
[17]
|
Steel, J.L., Geller, D.A., Gamblin, T.C., et al. (2007) De-pression, Immunity, and Survival in Patients with Hepatobiliary Carcinoma. Journal of Clinical Oncology, 25, 2397-2405. https://doi.org/10.1200/JCO.2006.06.4592
|
[18]
|
Calderaro, J., Rousseau, B., Amaddeo, G., et al. (2016) Pro-grammed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship with Clinical and Pathological Features. Hepatology, 64, 2038-2046.
https://doi.org/10.1002/hep.28710
|
[19]
|
Takada, K., Okamoto, T., Shoji, F., et al. (2016) Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology, 11, 1879-1890.
https://doi.org/10.1016/j.jtho.2016.06.006
|
[20]
|
Benson, A.B., D’Angelica, M.I., Abbott, D.E., et al. (2017) NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network, 15, 563-573.
https://doi.org/10.6004/jnccn.2017.0059
|
[21]
|
Gevensleben, H., Dietrich, D., Golletz, C., et al. (2016) The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 22, 1969-1977.
https://doi.org/10.1158/1078-0432.CCR-15-2042
|
[22]
|
Yokoyama, S., Miyoshi, H., Nakashima, K., et al. (2016) Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Clinical Cancer Research, 22, 4727-4734.
https://doi.org/10.1158/1078-0432.CCR-16-0434
|
[23]
|
Jelic, S. and Sotiropoulos, G.C. (2010) Hepatocellular Car-cinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 21, 59-64. https://doi.org/10.1093/annonc/mdq166
|
[24]
|
Kane, R.C., Farrell, A.T., Madabushi, R., et al. (2009) Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. Oncologist, 14, 95-100. https://doi.org/10.1634/theoncologist.2008-0185
|
[25]
|
Bruix, J., Raoul, J.-L., Sherman, M., et al. (2012) Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. Journal of Hepatology, 57, 821-829.
https://doi.org/10.1016/j.jhep.2012.06.014
|
[26]
|
Lee, H.W., Cho, K.J. and Park, J.Y. (2020) Current Status and Fu-ture Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Network, 20, e11. https://doi.org/10.4110/in.2020.20.e11
|
[27]
|
Yin, Z. and Li, X. (2020) Immunotherapy for Hepatocellular Carcino-ma. Cancer Letters, 470, 8-17.
https://doi.org/10.1016/j.canlet.2019.12.002
|
[28]
|
Sangro, B., Chan, S.L., Meyer, T., et al. (2020) Diagnosis and Management of Toxicities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Hepatology, 72, 320-341. https://doi.org/10.1016/j.jhep.2019.10.021
|
[29]
|
Rahma, O.E. and Hodi, F.S. (2019) The Intersection be-tween Tumor Angiogenesis and Immune Suppression. Clinical Cancer Research, 25, 5449-5457. https://doi.org/10.1158/1078-0432.CCR-18-1543
|
[30]
|
Roche, H.-L. (2021) A Study of the Safety and Efficacy of Atezolizumab Administered in Combination with Bevacizumab and/or Other Treatments in Participants with Solid Tu-mors. https://clinicaltrials.gov/ct2/show/NCT02715531
|
[31]
|
Lee, M.S., Ryoo, B.Y., Hsu, C.H., et al. (2020) Ate-zolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multi-centre, Phase 1b Study. The Lancet Oncology, 21, 808-820.
https://doi.org/10.1016/S1470-2045(20)30156-X
|
[32]
|
Kelley, R.K. (2020) Atezolizumab plus Bevacizumab—A Landmark in Liver Cancer. New England Journal of Medicine, 382, 1953-1955. https://doi.org/10.1056/NEJMe2004851 https://doi.org/10.1038/ajg.2014.11
|